A Study Based on Data From German Sick Funds That Looks at the Costs of Treatment of Type-2 Diabetic Patients With Empagliflozin vs. DPP-4 Inhibitors vs. GLP-1 Receptor Agonists
Clinical trial NCT04295005 · COMPLETED
Trial details
- NCT number
- NCT04295005
- Sponsor
- Boehringer Ingelheim
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2020-11-16
- Primary completion
- 2021-09-30
- Enrollment
- 24500
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.